1. Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R-Ankrd1-P53 Signaling Pathway.
- Author
-
Xu Z, Lu D, Yuan J, Wang L, Wang J, Lei Z, Liu S, Wu J, Wang J, and Huang L
- Subjects
- Animals, Rats, Apoptosis, Disease Models, Animal, Fibrosis, Muscle Proteins drug effects, Muscle Proteins metabolism, Myocardium metabolism, Myocytes, Cardiac metabolism, Nuclear Proteins drug effects, Nuclear Proteins metabolism, Receptor, Angiotensin, Type 1 drug effects, Receptor, Angiotensin, Type 1 metabolism, Repressor Proteins drug effects, Repressor Proteins metabolism, Signal Transduction, Tumor Suppressor Protein p53 drug effects, Tumor Suppressor Protein p53 metabolism, Drugs, Chinese Herbal pharmacology, Drugs, Chinese Herbal therapeutic use, Myocardial Infarction complications, Myocardial Infarction drug therapy, Myocardial Infarction metabolism
- Abstract
Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The AMI rat model was established by subcutaneous injection of Isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once/d for 7 days. Electrocardiogram, echocardiography, hemodynamic and cardiac enzyme in AMI rats were measured. HE, Masson, immunofluorescence and TUNEL staining were used to observe the degree of pathological damage, fibrosis and cardiomyocyte apoptosis in myocardial tissue, respectively. Expression of AT1R, CARP and their downstream related apoptotic proteins were detected by WB. The results demonstrated that storax could significantly improve cardiac electrophysiology and function, decrease serum cardiac enzyme activity, reduce type I and III collagen contents to improve fibrosis and alleviate myocardial pathological damage and cardiomyocyte apoptosis. It also found that storax can significantly down-regulate expression of AT1R, Ankrd1, P53, P-p53 (ser 15), Bax and cleaved Caspase-3 and up-regulate expression of Mdm2 and Bcl-2. Taken together, these findings indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R-Ankrd1-P53 signaling pathway.
- Published
- 2022
- Full Text
- View/download PDF